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Using Transitional Changes on High- Resolution Computed 
Tomography to Monitor the Impact of Cyclophosphamide 
or Mycophenolate Mofetil on Systemic Sclerosis–Related 
Interstitial Lung Disease
Grace Hyun J. Kim,1  Donald P. Tashkin,2 Pechin Lo,2 Matthew S. Brown,2 Elizabeth R. Volkmann,2   
David W. Gjertson,3 Dinesh Khanna,4  Robert M. Elashoff,2 Chi-Hong Tseng,2 Michael D. Roth,2 and  
Jonathan G. Goldin2
Objective. To examine changes in the extent of specific patterns of interstitial lung disease (ILD) as they transition 
from one pattern to another in response to immunosuppressive therapy in systemic sclerosis–related ILD (SSc- ILD).
Methods. We evaluated changes in the quantitative extent of specific lung patterns of ILD using volumetric high- 
resolution computed tomography (HRCT) scans obtained at baseline and after 2 years of therapy in patients treated 
with either cyclophosphamide (CYC) for 1 year or mycophenolate mofetil (MMF) for 2 years in Scleroderma Lung 
Study II. ILD patterns included lung fibrosis, ground glass, honeycombing, and normal lung. Net change was calcu-
lated as the difference in the probability of change from one ILD pattern to another. Wilcoxon’s signed rank test was 
used to compare the changes.
Results. Forty- seven and 50 patients had baseline and follow- up scans in the CYC and MMF groups, respective-
ly. Mean net improvements reflecting favorable changes from one ILD pattern to another in the whole lung in the CYC 
and MMF groups, respectively, were as follows: from lung fibrosis to a normal lung pattern, 21% and 19%; from a 
ground- glass pattern to a normal lung pattern, 30% and 28%; and from lung fibrosis to a ground- glass pattern, 5% 
and 0.5%. The mean overall improvement in transitioning from a ground- glass pattern or lung fibrosis to a normal 
lung pattern was significant for both treatments (all P < 0.001).
Conclusion. Significantly favorable transitions from both ground- glass and lung fibrosis ILD patterns to a normal 
lung pattern were observed in patients undergoing immunosuppressive treatment for SSc- ILD, suggesting the use-
fulness of examining these transitions for insights into the underlying pathobiology of treatment response.
INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a complex life- 
threatening autoimmune disease associated with tissue fibrosis. 
SSc- related interstitial lung disease (SSc- ILD) is common and is 
the leading cause of mortality in SSc (1–3). The majority of patients 
with SSc develop parenchymal abnormalities on high- resolution 
computed tomography (HRCT) of the chest, while only ~40% 
develop significant ventilatory restriction (forced vital capacity 
percent predicted [FVC%] <75%) and 10–15% develop severe 
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restrictive abnormality (FVC% <50%) (3,4). Most SSc patients 
develop ILD within the first 5–10 years of disease onset, and those 
with more severe restrictive abnormality are at greatest risk of pro-
gression to respiratory failure and death (5).
HRCT alterations characteristic of SSc- ILD include reticulations 
with architectural distortion (representing fibrosis); ground- glass 
opacity, defined as opacity through which normal lung markings may 
be visualized, representing either inflammation and/or early fibrosis; 
and, to a lesser extent, honeycombing (cystic air spaces with fibrous 
walls) (6). The combination of these elements represents the total 
burden of ILD that can broadly be assessed either visually or quanti-
tatively using image analysis software (6–15). Along with pulmonary 
function tests, the radiographic extent of disease in patients with 
SSc- ILD is important for diagnosis, the staging of disease sever-
ity, and the assessment of changes during follow- up (16,17). Fur-
thermore, changes in the extent of fibrosis (reticulations) assessed 
in the whole lung or in the most involved lobe either visually or by 
computer- aided quantitative analysis occur in parallel with changes 
in pulmonary function test findings in response to treatment with oral 
cyclophosphamide (CYC) or placebo over a 1- year period (18–20).
We previously reported transitional changes in the pixel- based 
quantitative extent of disease from one ILD pattern to another on 
paired HRCT scans obtained 1 year apart in 83 patients with SSc- 
ILD who participated in a trial of oral CYC (n = 41) versus placebo 
(n = 42) administered for 1 year (Scleroderma Lung Study I [SLS 
I]) (20). We found significantly greater changes over the 1- year 
course of the study from a fibrotic or a ground- glass pattern to a 
normal pattern than the reverse in the 41 CYC- treated patients, 
whereas the placebo- treated patients tended to show changes in 
the opposite direction. A limitation of that prior study was that the 
scans were nonvolumetric and were based on matching arbitrarily 
designated zones, thereby precluding the ability to quantitate the 
extent of ILD based on matching voxels and to segment the lung 
into lobes for analysis of voxelwise transitions within specific lobes.
To further explore transitional changes in the HRCT patterns 
of SSc- ILD as a sensitive and specific metric of disease progres-
sion and treatment response in patients with SSc- ILD, we now 
present the results of individual voxelwise changes over 2 years 
in HRCT patterns of quantitative lung fibrosis (QLF), quantitative 
ground- glass opacity (QGG), and quantitative normal lung (QNL) 
in both the whole lung and the most severely affected lobe in par-
ticipants in SLS II, a multicenter trial of oral CYC versus mycophe-
nolate mofetil (MMF) in patients with symptomatic SSc- ILD (21).
MATERIALS AND METHODS
Patient selection. Ninety- seven patients with symptomatic 
SSc- ILD (25 men and 72 women with a mean ± SD FVC% of 
66.3 ± 8.9% and diffusing capacity for carbon monoxide per-
cent predicted [DLco%] of 55.0 ± 13.1%) who participated in 
the 14- center SLS II and successfully underwent HRCT scans at 
screening (“baseline”) and 2 years following randomization were 
evaluated for the purpose of this exploratory outcome analysis. Eli-
gible participants were randomly assigned to receive, in a double- 
blind manner, either oral CYC (titrated to up to 2 mg/kg per day, 
as tolerated) for 1 year, followed by placebo for an additional year, 
or MMF (titrated to 1,500 mg twice daily, as tolerated) for 2 years. 
Full details concerning the SLS II methodology, including eligibility 
criteria, have been reported previously (21).
Measurements of FVC, DLco, total lung capacity (TLC), dys-
pnea (Mahler baseline dyspnea index [BDI] and transition dysp-
nea index [TDI]) (22), and skin thickness score (modified Rodnan 
skin thickness score [MRSS]) (23) were performed at baseline 
and repeated every 3 months (FVC, DLco, and MRSS) or every 6 
months (TLC and TDI) for 2 years (22,23). The study was approved 
by the local institutional review board of each participating institu-
tion. All radiographic image management was compliant with the 
Health Insurance Portability and Accountability Act.
CT scanning protocol. HRCT was used to scan patients 
at maximal inspiration. Images were acquired from 12 different 
multidetector CT scanner models from 2 manufacturers using a 
standardized procedure following strict quality control protocols. 
Most patients were scanned at suspended TLC in the prone posi-
tion (n = 92 prone at both visits, n = 4 supine at baseline and 
prone at 24 months or vice versa, and n = 1 supine position at 
both visits). Tube currents ranged from 80 to 100 effective mAs at 
120 kVp. Volumetric CT scans of 1–1.50- mm slice thickness were 
acquired and reconstructed with sharp or overenhancing filters. 
Ninety paired baseline and follow- up scans were acquired using 
the same CT scanner model.
Quantitative HRCT image analyses. Quantitative CT 
image analysis. Whole lung and individual lobes on HRCT imag-
es were segmented semiautomatically using an in- house analy-
sis workstation (24). Visual confirmation of lobar segmentation 
results was performed by a thoracic radiologist.
Probability of changes in CT scores for extent of ILD abnor-
mality during transition from one pattern of ILD to another. Quan-
titative CT texture- based scores of disease extent were derived 
from a supervised texture- based classification model (13). The 
following multistep process was used for generating voxelwise 
quantitative transitional probabilities from 97 paired HRCT scans: 
1) classifying ILD patterns using a computer- aided diagnosis 
(CAD) system that automatically processes and reduces HRCT 
image noise, calculating the texture features, and running the 
support vector machine model (13); 2) registering (superimpos-
ing) the lobes and each lung between baseline and 24 months 
(24); 3) mapping each voxel (<27 mm3) using a nearest- neighbor 
algorithm; and 4) counting the voxels within each mutually ex-
clusive pattern of ILD (fibrosis, ground glass, honeycombing, 
and normal) at baseline and 24 months, and calculating a transi-
tional probability (see Supplementary Figure 1 and Supplemen-
tary text, available on the Arthritis & Rheumatology web site at 
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for details of registration and transitional probability).
A transitional probability is an expression of the probability 
of changing from one radiographic pattern of ILD to another or 
retaining the same pattern, and is expressed as a proportion in 
which the numerator consists of the number of voxels represent-
ing a particular pattern of ILD that changes to another pattern 
(for example, a fibrotic pattern to a normal pattern) within a given 
region (whole lung or maximally involved lobe) between baseline 
and 24 months, and the denominator comprises the total  number 
of voxels within the initial pattern at baseline. The probability of 
stability is the proportion of the number of voxels remaining in the 
same pattern at 24 months compared to baseline. A Markov tran-
sitional matrix schema was used to illustrate the probabilities of 
changes from one ILD pattern to another within the whole lung or 
the most severely affected lobe (25).
Four types of quantitative CT CAD patterns were computed: 
QLF, comprising a fibrotic reticulation pattern only; QHC, com-
prising a honeycomb pattern; QGG, comprising a ground- glass 
pattern; and QNL, representing normal lung patterns. Since only 
2 of the 97 patients had a QHC >0 at baseline (one of 1.9% and 
the other of 5.3%) and the transitional probability of changing 
Figure 1. High- resolution computed tomography images of the lungs of a patient with systemic sclerosis–related interstitial lung disease (ILD) 
receiving cyclophosphamide. A and B, Coronal images of the whole lung (A) and sagittal images showing the right middle lobe (blue arrows) 
(B) obtained at baseline (left) and 24 months (right). Red and blue indicate quantitative lung fibrosis (LF); dark yellow indicates quantitative ground 
glass (GG). The remainder of the parenchymal area shows a quantitative normal (NL) lung pattern. C and D, Matrices showing transitional 
probabilities of change in ILD pattern in the whole lung (C) and the most severely affected lobe (the lower left lobe) (D). E, Three- dimensional 
rendering of coronal images showing normal lung pattern (green), quantitative lung fibrosis (blue and red), and a ground- glass pattern (yellow).
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from a honeycomb pattern to another pattern was 0, changes in 
a QHC pattern were omitted for simplicity and the 2 subjects with 
non- zero QHC scores were included in the QLF pattern under 
the assumption that honeycombing might represent a severe 
form of fibrosis. An example of a transitional probability from 
a lung fibrosis pattern to a ground- glass pattern is as follows: 
PLFat baseline → GG at follow-up = counts of voxels that convert from LF to 
GG patterns/total number of voxels classified as LF at baseline. 
A stable voxelwise pattern was represented as PNL→NL, PGG→GG, 
or PLF→LF, indicating the probability of a normal, ground- glass, or 
fibrotic pattern, respectively, remaining the same over 2 years. 
A transitional net improvement was defined as the difference 
in 2 probabilities, in which the probability of a transition repre-
senting worsening (e.g., a ground- glass pattern transitioning to 
a fibrotic pattern) is subtracted from the probability of a tran-
sition representing improvement (e.g., a fibrotic pattern chang-
ing to a ground- glass pattern). Three net improvements were: 
PGG→NL − PNL→GG; PLF → NL − PNL→LF; and PLF→GG − PGG→LF.
Statistical analysis. Descriptive summary statistics were 
used for reporting demographic and clinical characteristics, pul-
monary function measures, and quantitative CT texture scores at 
baseline and follow- up. CT scores are reported both for the whole 
lung and for the most severely affected lobe (the lobe with the 
greatest extent of disease as measured by the baseline QLF score) 
(26). We set up a 3 × 3 matrix consisting of the following transi-
tions: diagonal elements representing stability (PNL→NL, PGG→GG, or 
PLF→LF) and off- diagonals representing transitional changes (PLF→GG, 
PGG→LF, PGG→NL, PNL→GG, PLF→NL, and PNL→LF) (Figures 1C and D). Net 
improvement between patterns is represented by the difference 
between 2 probabilities, e.g., the probability of transitioning from a 
lung fibrosis pattern to a normal lung pattern minus the probability 
of the directionally opposite transition, i.e., from a normal lung pat-
tern to a lung fibrosis pattern (PLF→NL − PNL→LF).
After normality checks on a given metric, Wilcoxon’s 
signed rank test was performed to test for the significance of 
net improvement from baseline (e.g., PGG→LF versus PLF→GG [dif-
ference in proportions between opposite directional patterns]) 
for the CYC and MMF groups separately. Spearman’s rank 
correlations were used to test associations between changes 
in CT proportions in the whole lung and the most severely 
affected lobe and absolute changes in the percent predicted 
for pulmonary function test parameters. Linear regressions 
were used to determine the association of baseline demo-
graphic and clinical factors with the net benefit of change from 
ILD patterns of ground glass to normal and of lung fibrosis 
to normal. Backward selection methods were used with the 
covariates of age, sex, disease duration, pulmonary function, 
skin score, and dyspnea scores. A responder analysis was 
performed using +3% and −3.3% absolute changes in FVC% 
as the thresholds for defining responders and nonresponders, 
respectively. These thresholds represent previously published 
findings for the minimal clinically important differences for 
absolute changes in FVC% anchored to health- related out-
comes (27). Analysis of variance tests were used to compare 
the net improvements between the responder, stable, and 
nonresponder groups.
RESULTS
Baseline characteristics. Baseline demographic, lung 
function, clinical, and quantitative radiographic characteristics (the 
extent of fibrosis and total ILD in the whole lung and the lobe of 
maximal involvement) are shown in Supplementary Table 1, avail-
able on the Arthritis & Rheumatology web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41085/ abstract. Patients (n = 47 
in the CYC group and 50 in the MMF group) were predominantly 
women (74% [72 of 97]), were mostly middle- aged (mean ± SD 52 
± 9 years), and had, on average, moderate restrictive ventilatory 
and diffusion impairment (mean ± SD FVC% 66 ± 9% and DLco% 
55 ± 13%, respectively) and a moderate level of breathlessness 
(mean ± SD BDI 7.5 ± 2.3). The mean ± SD MRSS was 14 ± 
10, the extent of fibrosis was 23 ± 21%, and the extent of total 
ILD (fibrosis + ground glass + honeycombing) in the most severely 
involved lobe was 50 ± 22%.
Transitional proportion change. The mean ± SD 
duration between the baseline and follow- up CT scans was 
24.6 ± 1.9 months. Figure  1 depicts an example of paired 
HRCT scans and overlaid images of quantitative patterns with 
2 transitional matrices, one for the whole lung and the other 
for the most severely affected lobe (defined as the maximally 
involved lobe at baseline).
The mean transitional probability of change from each 
normal or ILD pattern (normal lung, ground glass, and lung 
fibrosis) to another pattern (e.g., from normal lung to ground 
glass; PNL→GG) or for remaining in the same pattern (e.g., from 
normal lung to normal lung; PNL→NL) for the whole lung and the 
most severely affected lobe is shown by treatment group in 
Table  1. There were no significant differences in transitional 
probabilities of change in ILD pattern between the 2 treatment 
groups (P = 0.52 for whole lung and P = 0.47 for the most 
severely affected lobe). Net improvements in ground- glass 
and fibrotic reticulation patterns, determined by subtracting 
unfavorable transitional probabilities from favorable ones (e.g., 
PLF→GG − PGG→LF), are shown in Table 2.
For the CYC group, mean transitional probabilities in the 
whole lung were as follows: 15% from fibrotic reticulation to 
ground glass (PLF→GG) and 10% from ground glass to fibrotic 
reticulation (PGG→LF) (Table  1), resulting in a net improvement 
(PLF→GG − PGG→LF) of 5% (Table 2); 25% from fibrotic reticulation 
to a normal pattern (PLF→NL), and 4% from a normal pattern to a 
fibrotic pattern (PNL→LF) (Table 1), with a net improvement (PLF→NL − 
PNL→LF) of 21% (Table 2); and 40% from a ground- glass pattern 
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to a normal pattern (PGG→NL) and 10% from a normal pattern to 
a ground- glass pattern (PNL→GG) (Table  1), with a net improve-
ment (PGG→NL − PNL→GG) of 30% (Table 2). For the MMF group, the 
net improvements in the whole lung were 0.5%, 19%, and 28% 
between fibrotic reticulation and ground- glass (PLF→GG − PGG→LF), 
between reticulation and a normal pattern (PLF→NL − PLF→NL), and 
between a ground- glass pattern and a normal pattern (PGG→NL − 
PNL→GG), respectively. Similar mean transitions were found in the 
most severely affected lobe (Table 1). There were no significant 
differences in the probability of 24-month change for total ILD 
between the 2 treatment groups (P = 0.52 for whole lung and 
P = 0.47 for the most severely affected lobe) (see Supplementary 
Table 2, available on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.41085/abstract).
The net improvements (or lack thereof) in the mean probabil-
ities for these transitional changes for each treatment group sep-
arately and combined are also illustrated by box plots in  Figure 2 
and by the Markov transition chain schema in Figure 3. The find-
ings demonstrate the mean net improvements in transitions from 
both lung fibrosis and a ground- glass pattern to a normal pattern in 
both treatment groups, but essentially no significant net improve-
ment in transitions from lung fibrosis to a ground- glass pattern.
Table  3 shows the associations between quantitative CT 
changes (from baseline to 24- month follow- up) and both 1) 
baseline demographic and clinical/radiographic characteristics 
and 2) changes in clinical outcomes of lung function, dyspnea, 
and skin score over the same time period. 
The clinical factors that were significantly associated with 
improvement from a ground- glass pattern to a normal pattern 
were high BDI scores (less baseline dyspnea) and female sex 
(adjusted R2 = 0.10). Baseline clinical factors associated with 
favorable transitions from lung fibrosis to a normal pattern were 
less restrictive ventilatory impairment (less reduction in FVC), 
high (worse) skin scores, and female sex (adjusted R2 = 0.16), by 
multivariate linear regression analysis.
Associations of transitional changes in ILD patterns 
with changes in relevant clinical features over 24 months are 
shown in the bottom portion of Table  3. The net improve-
ments from a ground- glass pattern to a normal pattern and 
from fibrotic reticulation to a ground- glass pattern showed 
statistically significant correlations with all pulmonary func-
tion test measurements (% predicted FVC, DLco, and TLC) 
in both the whole lung and the most severely affected lobe, 
while improvement from a fibrotic pattern to a normal pattern 
Table 2. Net improvement in ILD patterns based on voxelwise transitional changes*
Net improvement
Whole lung Most severely affected lobe
CYC MMF CYC MMF
PGG→NL – PNL→GG 0.30 ± 0.04† 0.28 ± 0.03† 0.17 ± 0.05‡ 0.14 ± 0.03§
PLF→GG – PGG→LF 0.05 ± 0.03 0.005 ± 0.03 −0.006 ± 0.04 −0.07 ± 0.04
PLF→NL – PNL→LF 0.21 ± 0.02† 0.19 ± 0.02† 0.12 ± 0.04¶ 0.07 ± 0.03#
* Net improvements were determined by subtracting unfavorable transitional probabilities 
(such as the probability of moving from a normal [NL] lung pattern to a ground- glass [GG] 
pattern [PNL→GG]) from favorable ones (such as the probability of moving from a ground- glass 
pattern to a normal lung pattern [PGG→NL]). Values are the mean ± SEM. ILD = interstitial lung 
disease; CYC = cyclophosphamide; MMF = mycophenolate mofetil; LF = lung fibrosis. 
† P < 0.001 versus a net improvement of 0. 
‡ P = 0.0008 versus a net improvement of 0. 
§ P = 0.0384 versus a net improvement of 0. 
¶ P = 0.0009 versus a net improvement of 0. 
# P = 0.017 versus a net improvement of 0. 

















Normal 0.86 ± 0.02 0.10 ± 0.01 0.04 ± 0.01 0.88 ± 0.01 0.09 ± 0.01 0.03 ± <0.01 0.87 ± 0.01 0.10 ± 0.01 0.03 ± <0.01
Ground glass 0.40 ± 0.17 0.50 ± 0.15 0.10 ± 0.13 0.37 ± 0.02 0.51 ± 0.02 0.12 ± 0.02 0.38 ± 0.02 0.50 ± 0.01 0.11 ± 0.01




Normal 0.76 ± 0.03 0.15 ± 0.02 0.09 ± 0.02 0.75 ± 0.03 0.14 ± 0.01 0.11 ± 0.0 0.75 ± 0.02 0.15 ± 0.01 0.10 ± 0.01
Ground glass 0.32 ± 0.03 0.52 ± 0.03 0.16 ± 0.03 0.28 ± 0.03 0.53 ± 0.02 0.19 ± 0.02 0.30 ± 0.20 0.53 ± 0.17 0.17 ± 0.02
Lung fibrosis 0.21 ± 0.03 0.16 ± 0.02 0.63 ± 0.04 0.18 ± 0.02 0.12 ± 0.02 0.70 ± 0.03 0.20 ± 0.02 0.14 ± 0.01 0.66 ± 0.02
* Values are the mean ± SEM. ILD = interstitial lung disease; CYC = cyclophosphamide; MMF = mycophenolate mofetil. 
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was significantly associated with improvements in FVC and 
TLC in the whole lung only. Net improvements from fibrotic 
reticulation to both normal and ground- glass patterns in both 
the whole lung and the most severely affected lobe were also 
significantly correlated with favorable changes in skin score 
but not with the TDI. The net improvements from fibrotic 
reticulation to a ground- glass pattern and from fibrotic reticu-
lation to a normal pattern showed significant correlations with 
changes in skin score in both the whole lung and the most 
severely affected lobe, whereas no significant  associations 
were found between radiologic net improvement and changes 
in dyspnea.
A responder analysis was also performed to assess whether 
favorable transitional changes in ILD patterns were associated 
with clinically meaningful changes in FVC% using previously 
published values for minimal clinically meaningful differences 
in FVC% over a 1- year time period. Results of this analysis 
are shown in Supplementary Table 3, available on the Arthri-
tis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41085/ abstract. Favorable transitional changes 
were uniformly greater in the responder and stable groups than 
in the nonresponder group, and differences across groups were 
significant, except for the transition from lung fibrosis to a normal 
pattern in the most severely affected lobe.
DISCUSSION
Treatment with either CYC for 1 year followed by placebo 
for an additional year, or with MMF for 2 years was associated 
with comparably significant increases in the probabilities of a net 
improvement from both ground- glass and fibrotic patterns of ILD 
to a normal lung pattern. Moreover, these favorable radiographic 
changes in the whole lung were associated with improvements in 
FVC and TLC, while the net improvement from a ground- glass to 
a normal pattern in both the whole lung and the most severely 
affected lobe was associated with improvements in DLco, FVC, 
and TLC. In addition, significant associations were found between 
the net improvement in fibrotic patterns and reduction in skin dis-
ease severity. These findings demonstrate that treatment- related 
improvements in structural patterns of ILD within the lung are 
accompanied by parallel improvements in lung function, as well 
as in extrapulmonary (cutaneous) involvement. Finally, transitional 
changes from a ground- glass pattern to a normal pattern, lung 
fibrosis to a ground- glass pattern, and lung fibrosis to a normal 
pattern were associated with minimal clinically important changes 
in FVC% that define either a positive response to immunosuppres-
sive therapy or at least stable lung function.
Although specific baseline characteristics were  significantly 
associated with favorable transitions from a ground- glass 
 pattern to a normal pattern (less dyspnea and female sex) or 
from lung fibrosis to a normal pattern (less restriction, worse 
skin scores, and female sex), these associations, while signif-
icant, were not strong (adjusted R2 0.10–0.16), underscoring 
the importance of clinical monitoring, including serial lung func-
tion measurements, along with judicious radiographic imaging.
This study provides further evidence that serial HRCT scans 
play an important and confirmatory role in monitoring the course 
of SSc- ILD. Patients with newly diagnosed SSc routinely undergo 
an initial HRCT scan as part of the assessment for the presence 
or absence of associated ILD with subsequent monitoring of lung 
function for evidence of the development or worsening of ILD 
(28). Follow- up HRCT scans may be warranted to confirm the 
development or worsening of ILD suggested by changes in lung 
function, given the variability and nonspecificity of lung  function 
Figure 2. Changes in interstitial lung disease (ILD) patterns in the 
whole lung (top) and most severely affected zone (bottom) in patients 
with systemic sclerosis–related ILD receiving cyclophosphamide 
(CYC), those receiving mycophenolate mofetil (MMF), and patients 
in both treatment groups combined. Patterns included lung fibrosis 
(LF), ground glass (GG), and normal lung (NL). Net improvements 
are expressed as the difference between 2 proportions (PLF→GG − 
PGG→LF, PLF→NL − PNL→LF, and PGG→NL − PNL→GG). Data are shown as 
box plots, where the boxes indicate the interquartile range, lines 
inside the boxes indicate the median, and whiskers indicate 1.5 x 
(75th−25th percentile). Circles indicate outliers. Broken lines indicate 
no difference in the transitional changes. Color figure can be viewed 
in the online issue, which is available at http://onlinelibrary.wiley.
com/doi/10.1002/art.41085/abstract.
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 measurements (which can be influenced by technical factors 
and/or inadequate patient effort [29,30]), in contrast to structural 
changes on HRCT that are more sensitive and specific indicators 
of parenchymal lung disease. The combination of lung function 
measurements and extent of ILD on HRCT has been suggested 
as a guide to decision- making regarding the initiation of disease- 
modifying therapy for SSc- ILD (16).
Continued monitoring of patients with established SSc- ILD 
already receiving immunosuppressive therapy with serial assess-
ments of lung function and symptoms (e.g., dyspnea and cough) 
may reveal equivocal findings (e.g., disparity between changes in 
lung function and dyspnea or between changes in FVC and DLco 
suggestive of pulmonary hypertension [31]) that might require a 
 follow- up HRCT scan for definitive assessment regarding whether 
or not ILD has progressed, in which case a modification of the 
therapeutic regimen might be indicated. A recent publication of 
serial changes in lung function performed at 3- month intervals and 
 follow- up HRCT scans in participants in SLS II provides some exam-
ples of patients with disparate changes in lung function and HRCT 
scans (32). Assessing the direction and magnitude of the quantitative 
Figure 3. Schema of transitions in interstitial lung disease (ILD) patterns in patients with systemic sclerosis (SSc)–related ILD by treatment 
group. A and B, Transitions between patterns in the whole lung in patients treated with cyclophosphamide (CYC) (A) and patients treated with 
mycophenolate mofetil (MMF) (B). Values are the probability of transition. In A, ‡ = P < 0.0001 for improvement from a ground- glass (GG) pattern 
to a normal (NL) pattern; § = P < 0.0001 for improvement from lung fibrosis (LF) to normal; P = 0.0568 for improvement from lung fibrosis to 
a ground- glass pattern. In B, * = P < 0.0001 for improvement from a ground- glass pattern to normal; # = P < 0.0001 for improvement from 
lung fibrosis to normal; P = 0.74 for improvement from lung fibrosis to a ground- glass pattern. C and D, Transitions between patterns in the 
most severely affected lobe in patients treated with CYC (C) and patients treated with MMF (D). Values are the probability of transition. In C, 
‡ = P = 0.0008 for improvement from a ground- glass pattern to normal; § = P = 0.0009 for improvement from lung fibrosis to normal; P = 0.87 
for improvement from lung fibrosis to a ground- glass pattern. In D, * = P = 0.0002 for improvement from a ground- glass pattern to normal, # = 
P = 0.017 for improvement from lung fibrosis to normal; P = 0.17 for improvement from lung fibrosis to a ground- glass pattern. Color figure can 
be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41085/abstract.
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voxelwise changes from one HRCT pattern of ILD to another repre-
sents a novel method of demonstrating the efficacy of treatment for 
SSc- ILD. This approach provides information on dynamic changes 
in the specific elements of structural abnormality of ILD patterns in 
the lung in response to treatment. This is both complementary to and 
more directly related to changes in abnormalities in lung structure than 
is the measurement of changes in lung function alone.
Interestingly, the net improvements in response to therapy 
that we noted were mainly from a fibrotic or a ground- glass pat-
tern to a normal pattern, not from a fibrotic to a ground- glass 
pattern. While the pathobiology of ground- glass opacity in SSc- 
ILD is not clear (e.g., whether it represents inflammatory changes 
in the lung or early fibrosis), it is plausible that lung inflammation 
in SSc- ILD may be a precursor to fibrosis as the disease pro-
gresses.
Interpreting changes in quantitative ground- glass scores with 
regard to improvement or worsening in SSc- ILD is confounded 
by the fact that a ground- glass pattern can transition either to a 
normal pattern and/or another abnormal pattern (i.e., fibrosis) and 
that changes in the extent of the ground- glass pattern can occur 
by 4 different routes (normal→ground glass, ground glass→nor-
mal, ground glass→fibrosis, or fibrosis→ground glass). In SLS II, 
the probability of a ground- glass pattern remaining the same was 
relatively high in both treatment groups (0.50 for whole lung and 
0.53 for the most severely affected lobe) (Table 1), but this “stabil-
ity” appeared to be due to a combination of changes from other 
patterns of ILD to a ground- glass pattern, as well as concomitant 
transitions from ground- glass patterns to other patterns. None-
theless, the clinically important findings were not transitions from 
lung fibrosis to a ground- glass pattern, but rather the net improve-
ment in response to immunosuppressive therapy was reflected 
by transitions from either lung fibrosis or a ground- glass pattern 
to a normal pattern. In addition, these findings indirectly support 
using reductions in total ILD (lung fibrosis + ground glass + hon-
eycombing) as an indication of treatment response in contrast to 
reductions in ground glass or fibrosis alone (33).
Table 3. Associations of transitional radiographic changes in ILD pattern with baseline characteristics and changes in lung function, skin 
score, and dyspnea*
Net improvement
Whole lung Most severely affected lobe
PGG→NL − PNL→GG PLF→GG − PGG→LF PLF→NL − PNL→LF PGG→NL − PNL→GG PLF→GG − PGG→LF PLF→NL − PNL→LF
Baseline
Male, % −0.26 (0.011) −0.24 (0.02) −0.15 (0.14) −0.24 (0.018) −0.23 (0.024) −0.16 (0.12)
Age, years 0.12 (0.23) −0.03 (0.74) −0.09 (0.37) 0.15 (0.15) −0.014 (0.89) −0.06 (0.56)
Disease duration −0.09 (0.37) −0.11 (0.30) −0.17 (0.10) −0.17 (0.10) −0.13 (0.19) −0.10 (0.34)
FVC% 0.04 (0.69) 0.23 (0.021) 0.39 (0.0001) 0.08 (0.45) 0.31 (0.0024) 0.38 (0.0001)
FEV1/FVC −0.24 (0.017) −0.15 (0.14) −0.20 (0.052) −0.16 (0.12) −0.18 (0.077) −0.17 (0.094)
DLco% 0.20 (0.0501) 0.23 (0.021) 0.33 (0.001) 0.24 (0.02) 0.25 (0.014) 0.30 (0.0025)
MRSS −0.07 (0.48) 0.11 (0.21) 0.15 (0.14) −0.03 (0.79) 0.10 (0.35) 0.10 (0.34)
BDI† 0.26 (0.011) 0.14 (0.20) 0.22 (0.03) 0.26 (0.012) 0.20 (0.049) 0.25 (0.014)
QLF, whole lung, % −0.29 (0.0046) −0.37 (0.0002) −0.67 (<0.0001) −0.32 (0.0013) −0.49 (<0.0001) −0.71 (<0.0001)
QILD, whole lung, % −0.31 (0.0018) −0.18 (0.07) −0.46 (<0.0001) −0.33 (0.0011) −0.30 (0.0025) −0.4881 (<0.0001)
QLF, most severely 
affected lobe, %
−0.30 (0.003) −0.40 (0.0001) −0.70 (<0.0001) −0.36 (0.0003) −0.53 (<0.0001) −0.77 (<0.0001)
QILD, most severely 
affected lobe, %
−0.35 (0.0004) −0.28 (0.0049) −0.60 (<0.0001) −0.43 (<0.0001) −0.43 (<0.0001) −0.69 (<0.0001)
24- month changes
Change in FVC% 0.33 (0.0009) 0.45 (<0.0001) 0.21 (0.036) 0.3368 (0.0007) 0.4078 (<0.0001) 0.1787 (0.0798)
Change in DLco% 0.24 (0.022) 0.23 (0.028) 0.08 (0.43) 0.20 (0.050) 0.21 (0.042) 0.14 (0.17)
% change in TLC 0.28 (0.0059) 0.31 (0.002) 0.21 (0.042) 0.32 (0.0017) 0.29 (0.004) 0.14 (0.18)
% change in FEV1/
FVC
0.02 (0.88) 0.03 (0.74) −0.03 (0.81) 0.00 (1.00) 0.11 (0.30) 0.05 (0.66)
Change in skin 
score‡
−0.107 (0.30) −0.27 (0.0066) −0.32 (0.0016) −0.13 (0.19) −0.25 (0.014) −0.29 (0.0043)
TDI§ 0.22 (0.059) 0.16 (0.19) 0.14 (0.25) 0.16 (0.18) 0.09 (0.46) −0.0028 (0.98)
* Values are Spearman’s rho (P). Net improvements were determined by subtracting unfavorable transitional probabilities (such as the proba-
bility of moving from a normal [NL] lung pattern to a ground- glass [GG] pattern [PNL→GG]) from favorable ones (such as the probability of moving 
from a ground- glass pattern to a normal lung pattern [PGG→NL]). ILD = interstitial lung disease; LF = lung fibrosis; FVC% = forced vital capacity % 
predicted; FEV1 = forced expiratory volume in 1 second; DLco% = diffusing capacity for carbon monoxide % predicted; MRSS = modified Rodnan 
skin thickness score; QLF = quantitative lung fibrosis; QILD = quantitative interstitial lung disease (QLF + quantitative ground glass + quantitative 
honeycombing – quantitative normal lung pattern); TLC = total lung capacity. 
† The Baseline Dyspnea Index (BDI) ranges from 0 (most severe) to 12 (unimpaired). Data were available for 89 patients. 
‡ For changes in skin score a negative value represents improvement and a positive value represents worsening. Data were available for 97 
patients. 
§ For transition dyspnea index (TDI) a negative value represents worsening and a positive value represents improvement. Data were available 
for 72 patients. 
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Our findings of a relatively high probability of lung fibrosis tran-
sitioning to a normal pattern (compared to the reverse) (0.24 for 
whole lung and 0.20 for the most severely affected lobe) (Table 1) 
are consistent with the previously reported radiographic results in 
SLS I, in which similar probabilities for these transitions in those 
receiving CYC were observed (0.19 for whole lung and 0.19 for 
the most severely affected zone) (20). Therefore, using two dif-
ferent approaches for quantifying the extent of different patterns 
of ILD, namely, voxelwise mapping of volumetric scans in SLS II 
and pixelwise hierarchical mapping using quantitative scores of 
2- dimensional scans in SLS I, provided confirmatory findings 
with regard to the partial resolution of lung fibrosis in response to 
immunosuppressive therapy.
On the other hand, numerically higher probabilities were found 
in the transitions from a ground- glass pattern to a normal pattern 
in the CYC group in SLS II (Table 1) compared to the CYC group 
in SLS I (0.40 versus 0.14, respectively, in the whole lung and 0.32 
versus 0.09, respectively, in the most severely affected lobe and 
zone at baseline) (20). This difference might be attributable to the 
differences between SLS II and SLS I in study populations, radio-
graphic techniques (CAD classifier with voxelwise versus pixelwise 
quantitative scores and segmentation into lobes versus arbitrarily 
defined zones), and duration of follow- up (2 years versus 1 year).
In calculating the probability of these voxelwise transitional 
changes, we used a new metric, namely “net improvement” 
(the results of which are presented in Table 2) to counter poten-
tial measurement error in the registration of the 2 paired HRCT 
images due to a misalignment in voxels, which could potentially 
occur in the measurement of both favorable and unfavorable 
changes. Thus, using the difference between 2 transitional prob-
abilities would be expected to reduce the impact of possible mis-
alignment from registration.
It is noteworthy that both treatment groups in SLS II demon-
strated relatively high probabilities of transitioning from either fibro-
sis or a ground- glass pattern to a normal lung pattern compared 
with changes in the reverse direction. These observations provide 
further support for the efficacy of both CYC and MMF in the man-
agement of symptomatic SSc- ILD, consistent with the favorable 
physiologic and patient- centered findings of SLS II, as previously 
described (21). These transitional changes may also provide insights 
into the pathobiology underlying responses to therapy for SSc- ILD. 
For example, it is possible that the changes from a ground- glass 
pattern to a normal pattern might represent complete resolution 
of fine, relatively loosely packed collagen fibrils, while the changes 
from a fibrotic to a normal pattern suggest that even coarser, more 
densely packed collagen is capable of complete resolution. The 
probability we observed of a net improvement from a fibrotic to 
a ground- glass pattern was close to 0, implying that the partial 
resolution of fibrosis in both SLS II and SLS I is reflected predom-
inantly by a transition directly to a normal lung pattern rather than 
by an intermediate pathway wherein coarse fibrosis transitions to 
a finer subresolution type of fibrotic pattern represented by ground 
glass. However, it is possible that concomitant changes from a 
ground- glass pattern to a normal pattern may have obscured this 
intermediate step in the resolution of frank fibrosis.
The results of our analysis should be interpreted within 
the context of certain limitations. First, the voxelwise registra-
tion between 2 HRCT scans obtained 2 years apart can be 
confounded by measurement variation. Second, the metric of 
probability of changes does not capture the absolute extent of 
the difference in scores for the different patterns (QLF, QGG, 
or QHC), although it does capture the directional and propor-
tional changes from baseline within these patterns of ILD. Third, 
while this metric of the probability of transitional changes in ILD 
patterns pertains to responses to immunotherapy for SSc- ILD 
mainly at the group level, its potential usefulness in the assess-
ment and management of individual patients requires further 
study. Fourth, as with any sensitive computer- aided diagnostic 
system, standardization, quality control of scanning equipment, 
and methodologies regarding acquisition techniques such as 
reconstruction kernel, slice thickness, and safe and diagnos-
tic levels of radiation are vitally important. Last, the transitional 
changes in ground glass and fibrotic reticulation based on the 
computer- aided classifier model using HRCT lack external vali-
dation by tissue histopathology.
Using voxel- by- voxel transitional scores on paired HRCT 
scans obtained 24 months apart during which patients with 
SSc- ILD were treated with MMF for the full 2 years or CYC for 
1 year followed by placebo, we observed changes in the extent 
of ILD patterns indicating comparably significant net transitions 
from both fibrotic reticulation and ground- glass opacity to a nor-
mal lung pattern. These results imply partial resolution of both 
coarse and fine fibrosis and support and extend previous find-
ings demonstrating improvement in lung function and clinical 
end points in response to treatment with MMF or CYC for SSc- 
ILD. These findings also demonstrate that voxelwise changes 
in ILD patterns of serial HRCT scans may be useful in monitor-
ing the response to treatment of SSc- ILD when other data are 
inconclusive and provide potential insights into the nature of the 
therapeutic effects of these two immunosuppressive agents.
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